News | May 17, 2024
Biocon posts Q4 FY24 PAT at Rs. 135 Cr
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
Cresset’s new India site will support the growing demands of Cresset’s APAC customer base
The company has posted net profit of Rs. 405.31 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 14.23 crores for the Financial Year ended March 31, 2024
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
The company has posted net profit of Rs.134.43 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.70.76 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs. 59.16 crores for the Financial Year ended March 31, 2024
Sanofi India has reported total income of Rs. 738.9 crores during the period ended March 31, 2024
Subscribe To Our Newsletter & Stay Updated
